Clinical trial

Efficacy and Safety of NVA237 in Patients With Chronic Obstructive Pulmonary Disease (COPD)

NCT01119950

Drugs and interventions used in this trial

8 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

Search this trial's interventions

DRUG · Unmapped registry intervention NVA237 12.5 µg once daily Find medicine records · Find other trials using this name

DRUG · Unmapped registry intervention NVA237 25.0 µg once daily Find medicine records · Find other trials using this name

DRUG · Unmapped registry intervention NVA237 12.5 µg twice daily Find medicine records · Find other trials using this name

DRUG · Unmapped registry intervention NVA237 50.0 µg once daily Find medicine records · Find other trials using this name

DRUG · Unmapped registry intervention NVA237 25.0 µg twice daily Find medicine records · Find other trials using this name

DRUG · Unmapped registry intervention NVA237 100.0 µg once daily Find medicine records · Find other trials using this name

DRUG · Unmapped registry intervention NVA237 50.0 µg twice daily Find medicine records · Find other trials using this name

DRUG · Unmapped registry intervention Placebo to NVA237 once daily Find medicine records · Find other trials using this name

Study at a glance

Registry-backed

Efficacy and Safety of NVA237 in Patients With Chronic Obstructive Pulmonary Disease (COPD)

Design: INTERVENTIONAL · Status: COMPLETED · Phase: PHASE2

Read study objectives, eligibility and outcome measures at ClinicalTrials.gov

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2010-04-01

PhasePHASE2

Conditions

Chronic Obstructive Pulmonary Diseaseverified · MONDO: chronic obstructive pulmonary disease

Interventions

NVA237 12.5 µg once dailyDRUG

NVA237 25.0 µg once dailyDRUG

NVA237 12.5 µg twice dailyDRUG

NVA237 50.0 µg once dailyDRUG

NVA237 25.0 µg twice dailyDRUG

NVA237 100.0 µg once dailyDRUG

NVA237 50.0 µg twice dailyDRUG

Placebo to NVA237 once dailyDRUG

Sponsors & collaborators

Novartis Pharmaceuticalslead sponsor

Mapped research locations

PhiladelphiaPennsylvania, United States1 San DiegoCalifornia, United States1 DenverColorado, United States1 OmahaNebraska, United States1 WarsawPoland1 BudapestHungary1 LodzPoland1 MünchenGermany1 TorranceCalifornia, United States1 DebrecenHungary1 A CoruñaSpain1 AlicanteSpain1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT01119950 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.